Chemomab Therapeutics Ltd. announced the completion of the Phase 3 design for Nebokitug PSC treatment after positive feedback from the FDA. EMA guidance supports a single Phase 3 trial with a composite endpoint. Phase 2 SPRING trial data presented at AASLD 2025 showed safety and biomarker improvements. New data highlights Nebokitug’s mechanisms relevant to PSC progression. Partnering options for Phase 3 program are advancing, with cash runway until Q4 2026.

At the recent AASLD 2025 conference, the PSC community voiced support for Nebokitug Phase 3 trial design. Regulatory agencies support a single Phase 3 trial with composite endpoint. Nebokitug’s potential as the first disease-modifying therapy for PSC is recognized. Discussions with potential partners are ongoing to support Phase 3 trial launch once funding is secured.

Data from Phase 2 SPRING trial at AASLD 2025 showed consistent positive effects of Nebokitug on key biomarkers in PSC patients. Nebokitug’s mechanism of action in halting disease progression was highlighted. Chemomab’s financial report for Q3 2025 shows a cash runway until Q4 2026. Regulatory alignment and clinical data support Nebokitug as a potential therapy for PSC.

Read more at GlobeNewswire: Chemomab Therapeutics Announces Third Quarter 2025